New Access Agreement with Scottish Government for Orkambi and Symkevi

Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)

Vertex to Acquire Semma Therapeutics

Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes

Triple Combo NDA Acceptance

FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment

Biotechnology to Create Transformative Medicines

At Vertex, we're relentless in our pursuit of medical research to create transformative medicines for people with serious and life-threatening diseases, like cystic fibrosis.

pipeline and medicine

PIPELINE & MEDICINES
Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
 

working here

WORKING HERE
At Vertex, we have some of the industry's best and brightest people helping us achieve our mission of discovering transformative medicines to help people with serious diseases, like cystic fibrosis. 

news

NEWS
Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)

Follow Us for Updates